Q-omics provides the consensus-scored RNA5SP389 profile across patient tissues and cancer cell-line models. RNA5SP389 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RNA5SP389 is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, RNA5SP389 RNA expression shows 4,355 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, and THYM as cancer lineages where RNA5SP389 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNA5SP389 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNA5SP389 survival associations across molecular data types. RNA5SP389 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNA5SP389 RNA expression–survival associations across cancer types. High RNA5SP389 expression shows unfavorable associations in STAD, ESCA, LIHC, READ, BRCA and LUSC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for RNA5SP389 RNA expression.
This table summarizes RNA5SP389 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNA5SP389. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNA5SP389 shows higher tumor expression in STAD. The STAD box plot shows higher RNA5SP389 RNA expression in tumor versus normal tissue (log2 FC = +0.464, t-test p < 0.001).
This table shows molecular features associated with RNA5SP389 in patient tissues and cancer cell lines. In patient samples, RNA5SP389 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
